Marshall Wace, LLP Kronos Bio, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.24 - $1.92 $76,746 - $118,832	-61,892 Reduced 32.89%	126,309 $217,000
Q1 2023 May 15, 2023	SELL	$1.34 - $2.62 $15,285 - $29,886	-11,407 Reduced 5.71%	188,201 $274,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $59,459 - $142,041	-41,291 Reduced 17.14%	199,608 $323,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $362,312 - $600,249	-108,153 Reduced 30.98%	240,899 $807,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $851,706 - $2.05 Million	272,983 Added 358.86%	349,052 $1.27 Million
Q1 2022 May 16, 2022	BUY	$6.26 - $14.42 $171,855 - $395,872	27,453 Added 56.47%	76,069 $550,000
Q2 2021 Aug 13, 2021	BUY	$20.08 - $29.02 $976,209 - $1.41 Million	48,616 New	48,616 $1.16 Million

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.